U.S. Markets close in 2 hrs 16 mins
  • S&P 500

    4,422.22
    +65.77 (+1.51%)
     
  • Dow 30

    34,592.34
    +294.61 (+0.86%)
     
  • Nasdaq

    13,872.37
    +333.07 (+2.46%)
     
  • Russell 2000

    2,035.24
    +31.21 (+1.56%)
     
  • Crude Oil

    87.29
    +1.69 (+1.97%)
     
  • Gold

    1,829.90
    -22.60 (-1.22%)
     
  • Silver

    23.80
    -0.10 (-0.40%)
     
  • EUR/USD

    1.1296
    -0.0010 (-0.0904%)
     
  • 10-Yr Bond

    1.7800
    -0.0030 (-0.17%)
     
  • Vix

    28.17
    -2.99 (-9.60%)
     
  • GBP/USD

    1.3514
    +0.0008 (+0.0622%)
     
  • USD/JPY

    114.2920
    +0.4260 (+0.3741%)
     
  • BTC-USD

    37,726.79
    +384.25 (+1.03%)
     
  • CMC Crypto 200

    866.99
    +11.18 (+1.31%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ADIL
  • Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs.

  • PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects across several therapeutic indications.

  • PNV-5030 has demonstrated more than 50 times greater solubility than other known selective adenosine compounds of the same class.

  • In the most recent study, PNV-5030 was tested in a mouse model of somatic nociceptive pain.

  • PNV-5030 alone exhibited a significant pain reduction compared to the control group and a similar effect to 1mg/kg morphine.

  • PNV-5030 demonstrated a significant effect when administered with 1 mg/kg morphine compared to 1 mg/kg morphine alone.

  • Combined with 1 mg/kg morphine, PNV-5030 achieved a similar level of pain reduction to the reduction obtained with 2mg/kg morphine.

  • The results indicate the possibility of lowering the opioid dose to achieve a similar pain reduction.

  • The Company expects to advance PNV-5030 into clinical trials in 2022.

  • Price Action: ADIL shares are down 7.18% at $3.88 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.